# Nuclide record breast-her2-positive (indication). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/indications/breast-her2-positive/>
  a schema:MedicalCondition ;
  nuclide:kind "indication" ;
  schema:identifier "breast-her2-positive" ;
  schema:name "HER2-positive breast cancer"@en ;
  schema:description "HER2-positive breast cancer was once the most aggressive subtype and is now one of the most treatable, thanks to trastuzumab and, more recently, Enhertu."@en ;
  schema:url <https://nuclide.cc/indications/breast-her2-positive/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/HER2-positive_breast_cancer> ;
  schema:citation <https://en.wikipedia.org/wiki/HER2-positive_breast_cancer> ;
  nuclide:tag "breast", "spike" ;
  nuclide:technologies <https://nuclide.cc/technologies/her2-pet/>, <https://nuclide.cc/technologies/fdg-pet/>, <https://nuclide.cc/technologies/site-specific-conjugation/> ;
  nuclide:targets <https://nuclide.cc/targets/her2/> ;
  nuclide:companies <https://nuclide.cc/companies/astrazeneca/>, <https://nuclide.cc/companies/pfizer/>, <https://nuclide.cc/companies/johnson-johnson/> ;
  nuclide:trials <https://nuclide.cc/trials/phergain/> ;
  nuclide:pipeline <https://nuclide.cc/technologies/her2-pet/>, <https://nuclide.cc/trials/phergain/> ;
  nuclide:standardOfCare <https://nuclide.cc/trials/phergain/> .